Company profile: FibroBiologics
1.1 - Company Overview
Company description
- Provider of fibroblast cell-based regenerative therapies for chronic diseases, including multiple sclerosis (immune modulation and tissue regeneration), CybroCell universal donor cellular product for degenerative disc disease (disc regeneration and inflammation reduction), wound healing, and therapies to improve and extend the productive life of the thymus and enhance spleen function.
Products and services
- Degenerative Disc Disease (DDD): CybroCell™ is a universal donor fibroblast cellular product that treats degenerative disc disease by promoting disc regeneration and reducing inflammation to restore disc function
- CNS Disorders (Multiple Sclerosis): FibroBiologics architects fibroblast cell-based therapies to treat multiple sclerosis by modulating immune responses and promoting tissue regeneration, aiming to improve neurological outcomes
- Skin (wound healing): FibroBiologics develops fibroblast cell-based therapies to enhance wound healing by supporting tissue repair and regeneration for improved recovery of skin integrity
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to FibroBiologics
Galectin Therapeutics
HQ: United States
Website
- Description: Provider of galectin-targeted therapeutics and research support, including belapectin (GR-MD-02) in clinical trials for NASH cirrhosis, cancer immunotherapy, and other fibrotic diseases; the NAVIGATE Phase 2b/3 study to prevent esophageal varices in NASH cirrhosis; combination trials with KEYTRUDA; discovery programs for small-molecule and carbohydrate galectin inhibitors; and galectin-3 inhibitor resources for preclinical studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Galectin Therapeutics company profile →
Zealand Pharma
HQ: Denmark
Website
- Description: Provider of peptide-based medicines and novel specialty drug candidates, leveraging leading-edge expertise and partnerships. Offerings include dasiglucagon for severe hypoglycemia (with Novo Nordisk), survodutide for obesity and MASH (with Boehringer Ingelheim), dapiglutide, and devices such as the investigational bihormonal iLet bionic pancreas (with Beta Bionics) and a continuous infusion pump for congenital hyperinsulinism (with DEKA Research).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zealand Pharma company profile →
Perrigo
HQ: Ireland
Website
- Description: Provider of a variety of over-the-counter and generic prescription pharmaceuticals as a pharmaceutical and consumer goods company.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Perrigo company profile →
Innovation Pharmaceuticals
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies addressing unmet medical needs, developing Brilacidin, a small-molecule drug candidate with immunomodulatory, anti-inflammatory, and antimicrobial properties tested for COVID-19, oral mucositis, inflammatory bowel disease, serious skin infections, and fungal diseases; and BEAMED, an image-guided surgical laser platform under development for treating cancer and epilepsy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Innovation Pharmaceuticals company profile →
SurfaceLogix
HQ: United States
Website
- Description: Provider of drug development leveraging biophysical chemistry to create new small molecule drugs with significantly improved pharmacokinetic and pharmacodynamic properties compared with class leaders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full SurfaceLogix company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for FibroBiologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to FibroBiologics
2.2 - Growth funds investing in similar companies to FibroBiologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for FibroBiologics
4.2 - Public trading comparable groups for FibroBiologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →